Novartis presents positive results from the pivotal phase III ASC4FIRST trial as a late-breaking abstract at the 2024 American Society of Clinical Oncology (ASCO) meeting. Scemblix (asciminib) demonstrated superior major molecular response (MMR) rates at week 48 compared to investigator-selected standard-of-care (SoC) tyrosine kinase inhibitors (TKIs) imatinib, nilotinib, dasatinib and bosutinib, and compared to imatinib alone in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP). Scemblix also showed a numerical improvement in MMR at week 48 vs. second generation (2G) TKIs (nilotinib, dasatinib and bosutinib). Additionally, Scemblix demonstrated a favourable safety and tolerability profile, with fewer adverse events (AEs) and treatment discontinuations vs. both imatinib and 2G TKIs.
Apotex`s Generic Nilotinib Hydrochloride Receives Approval in the U.S.
Aurobindo Pharma Limited has announced that its wholly owned subsidiary company, Eugia Pharma Specialities (Eugia), has entered voluntary sub-licensing agreement with Medicines Patent Pool (MPP), to develop and market Nilotinib Capsules, originally developed by Novartis, for the treatment of chronic myeloid leukemia (CML) in 44 Low and Middle-Income Countries (LMIC), including the seven countries where patents on the product are pending or in force.
Aurobindo Pharma on Friday said its wholly-owned arm, Eugia Pharma Specialities Ltd has entered into a voluntary sub-licensing agreement with Medicines Patent Pool (MPP) to develop and market an anti-cancer drug. The sub-licensing agreement for Nilotinib capsules, originally developed by Novartis, will be in 44 low and middle-income countries (LMIC), including the seven countries where patents on the product are pending or in force, Aurobindo Pharma said in a regulatory filing. nnnRead more at: nhttps://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/aurobindo-pharma-arm-signs-pact-with-medicines-patent-pool-to-develop-anti-cancer-drug/articleshow/101211337.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
More than a year ago, eight pharma giants partnered to provide cancer medicines to many of the world’s most needy nations where oncology treatments often are non-existent.
The Medicines Patent Pool has set up sublicense agreements with four manufacturers to produce generic versions of Novartis’ cancer drug Tasigna, as part of an ongoing effort to make access to medicines more equitable.
Geneva: Pharmaceutical giant Novartis has signed a licensing agreement increasing access to a vital leukaemia treatment, a UN-backed public health organisation said Thursday, marking the first-ever such agreement for a cancer drug.
The Medicines Patent Pool on Thursday unveiled a new voluntary licensing agreement with Novartis to increase access to its patented, second-line chronic myeloid leukemia drug Tasigna (nilotinib) in certain lower-income countries.
Apotex Inc's Generic Nilotinib Hydrochloride Receives Tentative Approval in the U.S.
Novartis thwarts Sun’s efforts to commercialize nilotinib in India, though the Indian firm indicates that its actions are covered under a local Bolar-type provision and that it has no plans to market the anticancer while the originator's patent stands valid.